Amoy Diagnostics Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in Xiamen in 2008 to its Shenzhen Stock Exchange debut under ticker 300685 in August 2017, Amoy Diagnostics Co., Ltd. (AmoyDx) has grown into a leading molecular diagnostics company for precision oncology-building a product portfolio that by 2020 included the AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic, forging a 2021 U.S. co-development partnership with Haihe Biopharma for Glumetinib (SCC244), and expanding distribution to over 500 hospitals in China and more than 50 countries; the company reported a 23.91% year-on-year revenue increase in 2024, surpassing 1 billion CNY in revenue with a net profit of 239 million CNY, and by December 2025 carried a market capitalization near 7.96 billion CNY (trailing P/E 27.87), supported by a diverse shareholder base led in part by founder-CEO Dr. Li-Mou Zheng, rigorous regulatory approvals (NMPA, MHLW, FDA), a robust R&D pipeline of PCR, NGS and FISH assays, and revenue streams from product sales, companion diagnostics partnerships, licensing and global distribution that underpin its push to scale precision oncology solutions worldwide.

Amoy Diagnostics Co., Ltd. (300685.SZ): Intro

• 2008 - Company founded in Xiamen, China, with an initial focus on molecular diagnostics for oncology precision medicine.
• August 2017 - IPO on the Shenzhen Stock Exchange (ticker: 300685), raising capital to accelerate R&D and expand manufacturing and commercialization capabilities.
• 2020 - Developed a comprehensive product portfolio; key product: AmoyDx® Pan Lung Cancer PCR Panel, approved in Japan as a companion diagnostic for selpercatinib.
• 2021 - Strategic partnership with Haihe Biopharma to co-develop a companion diagnostic for glumetinib (SCC244) targeting the U.S. market.
• 2024 - Reported revenue growth of 23.91% year-on-year, surpassing ¥1 billion CNY in revenue and achieving a net profit of ¥239 million CNY.
• Dec 2025 - Market capitalization approx. ¥7.96 billion CNY with a trailing P/E ratio of 27.87.

• Publicly listed entity (SZSE: 300685) with a mix of institutional investors, retail shareholders, and corporate insiders post-IPO.
• Governance structured with a board of directors, supervisory board, and executive management aligning R&D, regulatory, and commercial strategies.
• Collaborative alliances and licensing/partner agreements (e.g., Haihe Biopharma) expand geographic reach and CDx pipelines.

• Mission: Improve cancer patient outcomes by providing precise, accessible molecular diagnostics and validated companion diagnostics to guide targeted therapies.
• Vision: Be a leading global provider of oncology molecular diagnostics and CDx solutions that enable precision medicine at scale.
• Core values: scientific rigor, regulatory compliance, patient-centricity, and partnerships to accelerate clinical adoption.

• Core technologies: quantitative PCR-based panels, digital PCR, NGS-based assays, and validated companion diagnostic kits.
• Flagship product: AmoyDx® Pan Lung Cancer PCR Panel - used as a CDx for targeted therapies (e.g., selpercatinib in Japan).
• Pipeline: multiple tumor-specific panels and CDx assays developed for partner drug programs (e.g., glumetinib/SCC244 collaboration).

• Assay development - design, analytical validation, and clinical validation of molecular assays aligned to drug targets and clinical guidelines.
• Regulatory approval - seek national or regional registrations and CDx approvals (e.g., Japan CDx approval), including clinical-study support for label linkage.
• Manufacturing & distribution - scale production of IVD kits and distribution to hospitals, clinical labs, and oncology centers domestically and internationally.
• Service model - provide laboratory testing services (send-out testing) and partner with CROs/biopharma for trial diagnostics.
• Commercial channels - direct sales to hospitals, distributors, licensing to partners, and co-development/royalty structures with pharma collaborators.

• 2024 revenue: >¥1.00 billion CNY (23.91% YoY increase).
• 2024 net profit: ¥239 million CNY.
• Dec 2025 market capitalization: ~¥7.96 billion CNY; trailing P/E: 27.87.

• Focus on oncology CDx aligns with global precision oncology demand and targeted-therapy adoption.
• Regulatory approvals in markets like Japan and partnerships for U.S. market entry support international expansion.
• Diversified revenue mix (kits, services, partnerships) reduces single-channel concentration risk.
• Continuous R&D investments (post-IPO capital deployed to R&D and infrastructure) to expand assay menu and improve unit economics.

Amoy Diagnostics Co., Ltd. (300685.SZ): History

• Founded with a focus on PCR- and sequencing-based oncology assays and companion diagnostics.
• Expanded product portfolio to include infectious disease panels and liquid biopsy solutions.
• Invested in manufacturing and quality systems to meet both domestic and selected export regulatory standards.

• Public listing (300685.SZ) improved access to capital for R&D and capacity expansion-enabling multi-year revenue growth and margin improvements.
• Ownership concentration among institutions aligns incentives for regulatory compliance, financial transparency, and governance best practices.
• Insider ownership by the founder/CEO supports strategic continuity during international expansion and new product commercialization.

• Institutional backing: funds for manufacturing scale-up, clinical trials, and overseas registration efforts.
• Founder alignment: management retains meaningful upside, linking operational decisions to shareholder value.
• Market discipline: public reporting and regulatory oversight encourage rigorous financial controls and investor communications.

Amoy Diagnostics Co., Ltd. (300685.SZ): Ownership Structure

• Mission and values: AmoyDx is committed to enhancing patient outcomes worldwide through innovative molecular diagnostic solutions, with an emphasis on precision oncology and personalized treatment options.
• Quality and compliance: the company maintains rigorous quality systems and regulatory compliance across product development, registration, and distribution.
• Collaboration: active partnerships with top pharmaceutical firms to advance companion diagnostics and clinical trial testing services.
• R&D focus: sustained investment in research and development to expand assay panels, NGS workflows, and liquid biopsy capabilities.
• Global expansion: scaling distribution and regulatory filing efforts to make diagnostics accessible in Asia, Europe, and other markets.

• Product sales: clinical diagnostic kits (IHC, PCR, NGS panels) and reagents sold to hospitals, laboratories, and distributors.
• Service revenue: paid testing services, including NGS-based tumor profiling and companion diagnostic services for pharma trials.
• Collaborations and licensing: co-development agreements and licensing of assays to pharma partners for targeted therapies.
• After-sales and consumables: recurring revenue from reagents and consumables used in installed testing systems.

• Top shareholders typically combine founding group entities and institutional investors with a substantial public float on the Shenzhen Stock Exchange.
• Major stakeholders (representative allocation): founding group ~30-35%, institutional investors ~5-10%, public float ~55-65%.
• Board composition: mix of executive management with industry R&D leaders and independent directors to bolster governance and regulatory oversight.

• Robust NGS and PCR assay portfolio that addresses actionable oncogenic mutations and biomarkers used in targeted therapy decisions.
• Strong pharma collaborations for companion diagnostics, enabling co-commercialization opportunities and milestone/license revenue streams.
• High reinvestment into R&D (double-digit % of revenue) to expand panels, validation studies, and regulatory approvals across jurisdictions.

Amoy Diagnostics Co., Ltd. (300685.SZ): Mission and Values

• Core mission: accelerate precision oncology through validated molecular diagnostic tools that guide targeted therapies.
• Strategic values: clinical utility, quality systems, global access, and partnerships with pharma and healthcare providers.
• Operational focus: integrate R&D, regulatory strategy and commercial distribution to shorten time-to-clinic for companion diagnostics.

• Assay platforms: PCR-based panels, next-generation sequencing (NGS) panels, and fluorescence in situ hybridization (FISH) assays tailored to detect SNVs, indels, copy-number changes and gene fusions in tumors.
• Companion diagnostics: collaborative development with pharmaceutical companies to co-develop and validate companion diagnostics alongside targeted therapies, enabling label-linked testing and patient selection in clinical trials and post-approval use.
• R&D pipeline: in-house programs and co-development projects focusing on lung, colorectal, breast, gastric and hematologic malignancies, plus expansion into liquid biopsy and minimal residual disease (MRD) testing.
• Regulatory framework: maintains a structured quality and regulatory affairs function and has pursued approvals and clearances from major agencies, including the NMPA (China), MHLW (Japan) and interactions toward FDA pathways in the U.S. market.
• Commercial reach: leverages a global distribution network, serving over 500 hospitals in China and reaching more than 50 countries through direct sales, distributors and partner labs.

• Direct sales of diagnostic kits and reagents to hospitals and laboratories.
• Service revenue from testing performed in partner or company-operated labs (fee-for-service diagnostics).
• Co-development and licensing fees from pharmaceutical partners for companion diagnostics tied to drug development and commercialization.
• After-sales services: technical support, training, and regulatory/validation support for hospital laboratories.

• Pharma collaborations: multiple drug-development partnerships to deliver companion diagnostics for targeted oncology agents and immunotherapies; these partnerships generate co-development revenue and milestone payments.
• Regulatory approvals: active engagements with NMPA (China) for kit registrations, regulatory filings in Japan (MHLW pathway) and submissions/interaction toward U.S. regulatory pathways (FDA/CLIA partnerships) to support clinical adoption across markets.
• Quality systems: ISO and GxP-aligned quality systems underpin clinical trial assay validation and post-market surveillance.

Amoy Diagnostics Co., Ltd. (300685.SZ): How It Works

• Core product sales: in vitro diagnostic kits (PCR-based assays, NGS panels, single-gene companion diagnostics) sold to hospitals, third‑party testing labs, and distribution partners in China and abroad.
• Companion diagnostics (CDx) services: assay development and validation conducted in partnership with pharmaceutical companies to support targeted therapy approvals and clinical trials.
• Licensing & partnerships: revenue from out‑licensing proprietary assays, technology transfers, and co‑development agreements with domestic and international biotech/pharma firms.
• Service & testing revenue: fee income from contract testing, sample testing services, and platform use by clinical laboratories.
• R&D investment: sustained spending on new assay development, regulatory submissions (NMPA, CE-IVD, etc.), and NGS panel expansion to capture higher‑value diagnostics markets.

• Upfront and milestone payments from pharmaceutical partners for CDx co‑development and regulatory submissions.
• Recurring consumables and kit sales to clinical customers and distributors (high gross‑margin repeat revenue).
• Service fees for lab testing and contract research services.
• Royalties and licensing fees from technology transfer and authorized production.

• Consumable-driven recurring revenue yields higher gross margins than one‑time instrument sales.
• Companion diagnostic collaborations often include upfront payments and regulated revenue tied to drug approvals, improving predictability.
• Licensing deals and co‑development partnerships provide lump-sum and milestone income that can swing quarterly performance.
• Investment in NGS and high‑plex assays increases addressable market but raises short‑term R&D expense; successful approvals broaden margins long term.

• Regulatory approvals (NMPA, CE) expand access to hospital procurement channels and overseas markets.
• Partnerships with multinational pharma for CDx link diagnostics revenue to blockbuster drug launches.
• Expanding product portfolio-single‑gene kits, multiplex PCR, and targeted NGS panels-diversifies customer segments from oncology clinics to centralized labs.
• Sales and distribution networks in China plus growing export share underpin a dual domestic/international revenue base.

• AmoyDx negotiates co‑development agreements: typical structures include research fees, development milestones tied to clinical/regulatory events, and post‑approval royalties on CDx sales.
• Hospital and laboratory orders for kits and consumables provide recurring cash flow; procurement cycles and tenders affect timing.
• Contract testing services monetize excess laboratory capacity and provide clinical validation data supporting kit adoption.

Amoy Diagnostics Co., Ltd. (300685.SZ): How It Makes Money

• Core revenue streams: in vitro diagnostic (IVD) kits sales, companion diagnostic (CDx) development and licensing for oncology drugs, instrument sales and reagent consumables, and clinical testing services through hospital and lab partnerships.
• Pharma collaborations: fee-for-service and milestone/licensing payments from global pharmaceutical companies for CDx development tied to targeted therapies.
• Geographic mix: majority China sales with expanding export and distributor channels across Asia, Europe and select global markets.

• Market leader in Chinese oncology molecular diagnostics: AmoyDx holds a significant share in the domestic oncology IVD segment, especially in EGFR, ALK, ROS1 and multi-gene panels used for targeted therapy selection.
• Strategic pharma partnerships: collaborations with multinational biopharma companies bolster CDx pipelines and provide non-recurring revenues (milestones) plus long-term reagent and service demand.
• R&D-driven product expansion: sustained R&D spend supports next-generation sequencing (NGS) panels, digital PCR assays and automated platforms aimed at expanding indications beyond lung cancer into colorectal, breast and hematologic malignancies.
• International expansion: stepped-up regulatory and distribution efforts target Asia-Pacific and selected Western markets to capture unmet demand for localized oncology diagnostics.
• Financial health and growth indicators: healthy gross margins on kit/consumable sales, recurring revenue from reagent consumption, and diversified income from CDx licensing suggest capacity for sustained revenue growth and margin resilience as adoption of precision oncology increases.